UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1244-8
Program Prior Authorization/Notification
Medication Erleada® (apalutamide)
P&T Approval Date 5/2018, 5/2019, 11/2019, 11/2020, 11/2021, 11/2022, 11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Erleada (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with
non-metastatic castration-resistant prostate cancer. It is also indicated for the treatment of
metastatic castration-sensitive prostate cancer. Patients should also receive a gonadotropin-
releasing hormone (GnRH) analog concurrently while taking Erleada or should have had bilateral
orchiectomy.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the notification
criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Erleada will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Prostate Cancer
1. Initial Authorization
a. Erleada will be approved based on all of the following criteria:
(1) Diagnosis of prostate cancer
-AND-
(2) One of the following:
(a) Both of the following:
© 2024 UnitedHealthcare Services, Inc.
1
i. Disease is castration-resistant or recurrent
-AND-
ii. Disease is non-metastatic
-OR-
(b) Both of the following:
i. Disease is castration-sensitive or naive
-AND-
ii. Disease is metastatic
-AND-
(3) One of the following:
(a) Used in combination with a gonadotropin-releasing hormone (GnRH)
analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin),
Vantas (histrelin), Firmagon (degarelix)]
-OR-
(b) Patient has had bilateral orchiectomy
Authorization will be issued for 12 months.
2. Reauthorization Criteria
a. Erleada will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Erleada therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Erleada [package insert]. Horsham, PA: Janssen Products LP; August 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at NCCN
Drugs and Biologics Compendium®. Accessed October 8, 2024.
Program Prior Authorization/Notification – Erleada (apalutamide)
Change Control
5/2018 New program
5/2019 Annual review with no change to coverage criteria. Updated reference.
11/2019 Updated background and criteria to include new labeled indication in
metastatic castration-sensitive prostate cancer. Added general NCCN
recommendations for use statement. Updated references.
11/2020 Annual review. Minor formatting change. Updated references.
11/2021 Annual review with no change to coverage criteria. Updated references.
11/2022 Annual review with no changes to clinical coverage criteria. Updated
reference and added state mandate footnote.
11/2023 Annual review with no change to coverage criteria. Updated references.
11/2024 Annual review with no change to coverage criteria. Updated references.
© 2024 UnitedHealthcare Services, Inc.
3